AOD-9604
AOD-9604 (HGH Fragment 176–191)
A fragment of human growth hormone (amino acids 176–191) studied specifically for fat metabolism without the growth-promoting or glucose-altering effects of full HGH.
AOD-9604 is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
AOD-9604 is a modified fragment of the C-terminus of human growth hormone, specifically amino acids 176 through 191 with an added tyrosine residue at the N-terminus. It was developed by Monash University in Australia.
The rationale for isolating this fragment was that the fat-burning properties of HGH appear to reside in this region, while growth-promoting effects are mediated elsewhere. AOD-9604 received GRAS (Generally Recognized As Safe) designation from the FDA for oral use, making it one of the few research peptides with any formal US regulatory recognition.
What research shows
- Stimulates fat breakdown (lipolysis) and inhibits fat formation (lipogenesis) in animal models
- No significant effect on IGF-1 levels, distinguishing it from full HGH
- No impact on blood glucose — unlike growth hormone
- Some Phase 2 clinical data for weight loss (results were modest)
- Ongoing research into osteoarthritis treatment with promising early signals
What remains unknown
- Clinically meaningful weight loss benefit in humans — trials to date have been underwhelming
- Long-term safety profile
- Optimal route of administration (oral vs. injection) for systemic fat loss
Administration basics
Common use cases
Fat loss support, body composition. Often used alongside other peptides in weight management protocols.
Half-life
~30 minutes.
Administration
Subcutaneous injection. Oral formulations studied but systemic bioavailability is limited.
Source this compound
Looking for AOD-9604?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Phase 2 clinical trials used 500mcg/day subcutaneously
- Community protocols commonly report 300–500mcg per injection, once daily
Administration routes studied
Typical protocol duration
Phase 2 trials ran 12 weeks. Community protocols commonly report 8–12 week cycles.
Common stacking protocols
- AOD-9604 + Ipamorelin/CJC-1295 — combined in body composition protocols targeting fat loss with GH support
- AOD-9604 + Semaglutide — occasionally combined in community weight management protocols; no formal research on this combination
Contraindications & combinations to avoid
- Full-length HGH — combining AOD-9604 with exogenous growth hormone has overlapping mechanisms and no established benefit
- Active thyroid disease — fat metabolism pathways may be affected; consult a physician
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with AOD-9604 and what to avoid.
Track your AOD-9604 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the AOD-9604 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.